Artificial intelligence for predicting BCG response in non‐muscle‐invasive bladder cancer: a systematic review
- 17 August 2026
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 138 (5) , 786-797
Abstract
Objectives: To systematically identify, appraise and synthesise artificial intelligence (AI) and machine‐learning (ML) models that predict treatment response and clinical outcomes after intravesical bacillus Calmette–Guérin (BCG) in non‐muscle‐invasive bladder cancer (NMIBC), a setting in which current risk calculators underperform, and identifying non‐responders has become urgent as alternatives to BCG enter practice. Methods: PubMed, EMBASE and Web of Science were searched through April 2026 following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 guidelines (International Prospective Register of Systematic Reviews [PROSPERO] number CRD420261376808). Studies developing or validating AI/ML models for BCG‐associated outcomes with a quantitative performance metric were included. Risk of bias was assessed with the Prediction model Risk Of Bias ASsessment Tool (PROBAST). Evidence was synthesised along a clinically oriented framework: AI as a perceptual tool (extracting signal from histology or imaging) or integrative tool (re‐weighting clinicopathological, molecular, or urinary variables). Results: A total of 15 studies (>24 900 patients) were included: seven perceptual, eight integrative. By input data, six used digital pathology, two radiomics, two genomics/transcriptomics, four clinicopathological markers, and one urinary biomarkers. The digital‐pathology Computational Histology Artificial Intelligence (CHAI) platform, validated across 12 international centres, stratified high‐grade recurrence (hazard ratio [HR] 2.08), progression (HR 3.87) and BCG‐unresponsive disease (HR 2.31), and was the only model providing a first signal of predictive value, demonstrating a significant BCG vs gemcitabine/docetaxel interaction ( P = 0.029). Integrative models PROGRxN‐BCa (concordance index [C‐index] 0.79) and DeepSurv (C‐index 0.881) outperformed standard calculators but with modest gains (ΔC‐index 0.05–0.10). Only 40% of studies performed external validation, none prospectively; five were at high risk of bias. Conclusion: Perceptual AI, particularly digital pathology, has the highest external validation and provides the only biomarker with a first signal of predictive value for BCG vs alternatives, increasingly relevant in the context of the global BCG shortage. Integrative models such as PROGRxN‐BCa and DeepSurv outperform standard calculators with incremental gains and are freely accessible. Prospective validation, systematic calibration reporting and treatment‐by‐biomarker interaction analyses, ideally embedded in trials such as the BRIDGE trial (ClinicalTrials.gov identifier: NCT05538663), remain priorities before clinical adoption.Keywords
This publication has 35 references indexed in Scilit:
- Presence of an Artificial Intelligence–powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non–muscle-invasive Bladder CancerEuropean Urology Oncology, 2025
- Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non-muscle-invasive bladder cancer: a retrospective, multicentre studyeClinicalMedicine, 2025
- Stability of clinical prediction models developed using statistical or machine learning methodsBiometrical Journal, 2023
- Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non–muscle-invasive Bladder Cancer (BRIDGE)European Urology Focus, 2023
- Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non–muscle-invasive Bladder Cancer Treated with Bacillus Calmette-GuérinEuropean Urology Oncology, 2022
- Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non–muscle-invasive Bladder CancerEuropean Urology Oncology, 2022
- European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines PanelEuropean Urology, 2021
- Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic ReviewEuropean Urology, 2018
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Patient-recognition data-mining model for BCG-plus interferon immunotherapy bladder cancer treatmentComputers in Biology and Medicine, 2005